India pharma quality lapses force U S. to look to China for vital drugs
This is because in India, there is an inadequate R&D infrastructure and lower industry-academia connection for research. As mentioned above, DPCO establishes the various pricing parameters according to which the price is to be decided, and this policy reduces the profitability of the companies that would invest in innovative drugs, which requires huge capital. This …
India pharma quality lapses force U S. to look to China for vital drugs Read More »